7 Major Market Adrenocortical Carcinoma Epidemiology Forecast Report 2020-2034: Focus on United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan - ResearchAndMarkets.com

The "Adrenocortical Carcinoma - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

The report delivers an in-depth understanding of Adrenocortical Carcinoma (ACC), historical and forecasted epidemiology of Adrenocortical Carcinoma (ACC) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

For the purpose of designing the patient-based model for ACC, the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of ACC, Stage-specific Incident Cases of ACC, Gender-specific Incident Cases of ACC, and Age-specific Incident Cases of ACC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

As per estimates, Japan accounted for nearly 20% of the Total Incident Cases of ACC in the 7MM in 2023. According to the analysis, among the EU4 and the UK, Germany reported the highest incidence of ACC with approximately 168 cases, followed by France with nearly 136 cases. Spain had the lowest incidence, with 94 cases. These figures are projected to increase by 2034.

The Gender-specific Cases of ACC in the US were ~195 for females and ~145 for males in 2023 and are expected to increase within the forecast period (2024-2034). The increased incidence in females is likely due to a combination of factors, including genetics, environmental factors, and healthcare inequalities, among others.

According to expert analysis, the age-specific cases of Adrenocortical Carcinoma (ACC) were categorized into < 20 years, 20-40 years, 40-60 years, and >60 years. In 2023, the highest number of cases (~132) was observed in the >60 years age group in the US.

The analysis for 2023 indicates that stage-specific incident cases of ACC in Japan were divided into Stage I, Stage II, Stage III, and Stage IV. The highest incidence was observed in Stage IV with approximately 102 cases, while Stages I and II had the lowest, at around 29 cases each. This variation reflects distinct disease progression rates. Projections suggest these numbers will increase significantly, showing a robust compound annual growth rate over the forecast period.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease incidence.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Michigan, Ann Arbor, MI, US, Interfaith Medical Center, Brooklyn, NY, US, Wurzburg University Hospital, Wurzburg, Germany, Center Leon-Berard, Department of Medical Oncology, Lyon, France, University-Hospital of Padua, Padua, Italy, Catalan Institute of Oncology, Barcelona, Spain, University Hospital of Wales, Cardiff, United Kingdom, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, and others were contacted. Their opinion helps understand and validate current disease incidence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Key Highlights

• The analyst projects that the total incident cases of Adrenocortical Carcinoma (ACC) in the 7MM were ~1,245 in 2023 and these cases are going to increase during the forecast period (2024-2034). This increase in growth can be attributed to growing awareness, ultimately leading to an increase in the occurence of ACC.
• According to analysis, approximately 27% of the total incident cases of ACC in the 7MM were in the United States. Our estimations indicate that in 2023, the EU4 and the UK collectively represented nearly 658 incident cases of ACC.
• The analysis indicates that, in 2023, the stage-specific incident cases of ACC in the United States were highest in stage III, with 130 cases, and lowest in stage I, with 50 cases. These numbers are expected to rise significantly, growing at a notable compound annual growth rate (CAGR) over the forecast period.
• According to analysis, in 2023, Japan's gender-specific incident cases of ACC were predominantly female, accounting for 70% of cases, while males represented 30%. This distribution underscores a significant gender disparity in ACC incidence, pointing to potential biological or environmental factors influencing higher incidence in females.

Scope of the Report

• The report covers a segment of executive summary, descriptive overview of Adrenocortical Carcinoma (ACC), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Adrenocortical Carcinoma (ACC) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Incident Cases of ACC
• Stage-specific Incident Cases of ACC
• Gender-specific Incident Cases of ACC
• Age-specific Incident Cases of ACC

Adrenocortical Carcinoma (ACC) Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Adrenocortical Carcinoma (ACC) Epidemiology Segmentation

Adrenocortical Carcinoma (ACC) Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Adrenocortical Carcinoma (ACC)? What will be the growth opportunities across the 7MM concerning the patient population of Adrenocortical Carcinoma (ACC)?
• What is the historical and forecasted Adrenocortical Carcinoma (ACC) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the incident cases of ACC in Japan lower than the US?
• Which country has a high patient share for ACC?

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Adrenocortical Carcinoma (ACC) Epidemiology Overview at a Glance

3.1. Patient Share Distribution of ACC in 2020

3.2. Patient Share Distribution of ACC in 2034

4. Epidemiology Forecast Methodology

5. Executive Summary

6. Disease Background and Overview

6.1. Introduction

6.2. Stages of ACC

6.3. Causes and Risk Factors

6.4. Pathophysiology

6.5. Symptoms and Clinical Presentations

6.6. Diagnosis

6.6.1. Diagnostic Algorithm

6.6.2. Diagnostic Guidelines

6.6.2.1. NCCN Guidelines for Patients: ACC

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Assumptions and Rationale: The 7MM

7.2.1. Incident Cases of ACC

7.2.2. Stage-specific Incident Cases of ACC

7.2.3. Gender-specific Incident Cases of ACC

7.2.4. Age-specific Incident Cases of ACC

7.3. Total Incident Cases of ACC in the 7MM

7.4. The United States

7.5. EU4 and the UK

7.5.1. Germany

7.5.2. France

7.5.3. Italy

7.5.4. Spain

7.5.5. The United Kingdom

7.6. Japan

8. Patient Journey

9. Key Opinion Leaders' Views

10. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/utr9xb

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250415292561/en/